Earnings summaries and quarterly performance for Inogen.
Executive leadership at Inogen.
Kevin R.M. Smith
Detailed
Chief Executive Officer and President
CEO
GR
Gregoire Ramade
Detailed
Executive Vice President, Chief Commercial Officer
JY
Jennifer Yi Boyer
Detailed
Executive Vice President, Enterprise Enablement and Chief Human Resources Officer
KP
Kevin P. Smith
Detailed
Executive Vice President, General Counsel, Secretary & Business Development
MW
Mary Wright
Detailed
Chief Accounting Officer
MB
Michael Bourque
Detailed
Executive Vice President, Chief Financial Officer, and Corporate Treasurer
Board of directors at Inogen.
EM
Elizabeth Mora
Detailed
Chairperson of the Board
GB
Glenn Boehnlein
Detailed
Director, Chairperson of the Audit Committee
HR
Heather Rider
Detailed
Director, Chairperson of the Nominating and Governance Committee
KK
Kevin King
Detailed
Director, Chairperson of the Compliance Committee
MK
Mary Kay Ladone
Detailed
Director, Chairperson of the Compensation Committee
MS
Mira Sahney
Detailed
Director
Research analysts who have asked questions during Inogen earnings calls.
AS
Anderson Schock
B. Riley Securities
3 questions for INGN
Also covers: ANIK, CLPT, ELMD +8 more
Joseph Conway
Needham & Company, LLC
3 questions for INGN
Also covers: AORT, ATRC, ENOV +6 more
RP
Rohin Patel
JPMorgan Chase & Co.
3 questions for INGN
Also covers: CVRX, HAE, NPCE
CC
Colin Clark
Stifel Financial Corp.
2 questions for INGN
Also covers: DXCM
Michael Matson
Needham & Company
2 questions for INGN
Also covers: AORT, ATRC, CNMD +22 more
AG
Allen Gong
JPMorgan Chase & Co.
1 question for INGN
Also covers: ESTA, GEHC, GKOS +3 more
MS
Max Smock
William Blair & Company
1 question for INGN
Also covers: CDMO, CERT, CRL +8 more
Mike Matson
Needham & Company, LLC
1 question for INGN
Also covers: AORT, ATRC, CNMD +19 more
Recent press releases and 8-K filings for INGN.
Inogen Reports Q4 and Full Year 2025 Results, Provides 2026 Guidance and Announces Share Repurchase Program
INGN
Earnings
Guidance Update
Share Buyback
- Inogen reported Q4 2025 revenue of $82 million and full-year 2025 revenue of $349 million, reflecting 4% year-over-year growth.
- The company achieved positive adjusted EBITDA of $2.7 million for the full year 2025, its first since 2021, and significantly reduced its adjusted net loss to $8 million.
- Inogen ended 2025 with $120.9 million in cash equivalents and no debt, and its board authorized a $30 million share repurchase program for 2026 and 2027.
- For 2026, Inogen initiated full-year revenue guidance of $366 million-$373 million, representing approximately 6% year-over-year growth at the midpoint, and expects to continue to drive positive adjusted EBITDA.
- The company diversified its portfolio in 2025 with new product launches including Voxi 5, Simeox, and Aurora CPAP masks, expanding its total addressable market from $400 million to over $3 billion.
Feb 24, 2026, 10:00 PM
Inogen Reports Q4 and Full-Year 2025 Results, Announces Share Repurchase Program, and Provides 2026 Guidance
INGN
Earnings
Guidance Update
Product Launch
- Inogen reported Q4 2025 revenue of $81.7 million and full-year 2025 revenue of $348.7 million, reflecting 4% year-over-year growth. The company achieved positive Adjusted EBITDA of $2.7 million for the full year 2025, marking its first Adjusted EBITDA profitability since 2021.
- The company ended 2025 with a strong balance sheet, holding $120.9 million in cash equivalents and no debt. The Board of Directors authorized a $30 million share repurchase program to be executed over 2026 and 2027.
- Inogen is transforming into a diversified respiratory care platform, expanding its product portfolio with Voxi 5, Simeox, and Aurora CPAP masks, which has expanded its total addressable market from $400 million to over $3 billion. International business showed strong growth, with Q4 revenue up 15% year-over-year.
- For full-year 2026, Inogen expects revenue growth of approximately 6% year-over-year, with guidance between $366 million and $373 million, and anticipates continued positive Adjusted EBITDA. Long-term goals include high single-digit revenue growth and 10% or better Adjusted EBITDA over the next three to five years.
Feb 24, 2026, 10:00 PM
Inogen Announces Q4 and Full Year 2025 Results
INGN
Earnings
Demand Weakening
- Total revenue for Q4 2025 reached $81.7 million, reflecting a 2.0% quarter-over-quarter growth and 3.9% year-over-year growth. For the full year 2025, total revenue was $348.7 million.
- The company reported a net loss of $(7,127) thousand for Q4 2025 and a net loss of $(22,747) thousand for the full year 2025.
- Adjusted EBITDA (non-GAAP) was $(1,680) thousand in Q4 2025 and $2,693 thousand for the full year 2025.
- Total operating expenses were $44,542 thousand in Q4 2025 and $184,472 thousand for the full year 2025.
Feb 24, 2026, 10:00 PM
Inogen Reports Q4 and Full Year 2025 Results, Outlines Strategic Transformation and 2026 Guidance
INGN
Earnings
Guidance Update
Product Launch
- Inogen reported $348.7 million in total revenue for full year 2025, a 4% year-over-year increase, and $81.7 million for Q4 2025, up 2%. The company achieved positive adjusted EBITDA of $2.7 million for the full year 2025, marking its first positive adjusted EBITDA year since 2021.
- The company has transformed from a single-product oxygen company into a diversified respiratory care platform, expanding its estimated total addressable market from approximately $400 million to over $3 billion with new product launches including Voxi 5, Simeox, and Aurora CPAP masks.
- Inogen ended 2025 with $120.9 million in cash equivalents, marketable securities, and restricted cash and no debt , and its board authorized a $30 million share repurchase program for 2026 and 2027.
- For full year 2026, Inogen expects revenue between $366 million and $373 million, representing approximately 6% year-over-year growth at the midpoint, and anticipates continued positive adjusted EBITDA.
Feb 24, 2026, 10:00 PM
Inogen Announces Q4 and Full Year 2025 Financial Results and Provides 2026 Outlook
INGN
Earnings
Guidance Update
Share Buyback
- Inogen reported full year 2025 revenue of $348.7 million, an increase of 3.9% from the prior year, with a net loss of $22.7 million and positive adjusted EBITDA of $2.7 million.
- For the fourth quarter of 2025, total revenue was $81.7 million, a 2.0% increase from the prior-year period, with a GAAP net loss of $7.1 million and negative adjusted EBITDA of $1.7 million.
- The company provided a full year 2026 revenue outlook in the range of $366 million to $373 million, reflecting approximately 6% growth at the midpoint, and is committed to driving positive Adjusted EBITDA improvement in 2026.
- Inogen authorized a $30.0 million share repurchase program, supported by a strong balance sheet with $120.9 million in cash, cash equivalents, marketable securities, and restricted cash, and no debt outstanding as of December 31, 2025.
Feb 24, 2026, 9:06 PM
Inogen Announces Fourth Quarter and Full Year 2025 Results and 2026 Outlook
INGN
Earnings
Guidance Update
Share Buyback
- Inogen reported full year 2025 revenue of $348.7 million, an increase of 3.9%, with a net loss of $22.7 million and positive adjusted EBITDA of $2.7 million, marking its first positive adjusted EBITDA since 2021.
- For the fourth quarter of 2025, total revenue increased 2.0% to $81.7 million, and adjusted EBITDA improved by 52.8% to negative $1.7 million.
- The company provided full year 2026 revenue guidance in the range of $366 million to $373 million, reflecting approximately 6% growth at the midpoint, and expects to drive positive Adjusted EBITDA improvement in 2026.
- Inogen concluded 2025 with $120.9 million in cash, cash equivalents, marketable securities, and restricted cash, with no debt outstanding, and authorized a $30.0 million share repurchase program.
Feb 24, 2026, 9:05 PM
Inogen Announces Share Repurchase Program
INGN
Share Buyback
- Inogen's Board of Directors has authorized a share repurchase program for up to $30 million of its outstanding common stock.
- The program is intended to reflect confidence in Inogen’s strategy, progress towards profitability goals, and long-term growth trajectory, while enhancing shareholder value.
- It will be financed through cash flow and existing cash reserves and is authorized until December 31, 2027, or until the maximum amount is utilized.
Feb 24, 2026, 9:00 PM
Inogen Announces Preliminary Q4 and Full-Year 2025 Revenue Results
INGN
Earnings
Guidance Update
- Inogen announced preliminary, unaudited total revenue of approximately $82 million for the fourth quarter of 2025, representing year-over-year growth of approximately 2%.
- For the full year 2025, preliminary, unaudited total revenue is expected to be approximately $349 million, reflecting year-over-year growth of approximately 4%.
- The company anticipates achieving positive Adjusted EBITDA for the full year 2025.
- Management noted that Q4 results were impacted by a shift in the timing of some large customer orders into the first half of 2026.
- Inogen plans to announce full financial results and 2026 financial guidance on February 24, 2026.
Jan 12, 2026, 1:41 PM
Inogen Announces Preliminary Q4 and Full-Year 2025 Revenue Results
INGN
Earnings
Guidance Update
- Inogen announced preliminary, unaudited total revenue for Q4 2025 is estimated at approximately $82 million, reflecting 2% year-over-year growth.
- For the full year 2025, preliminary, unaudited total revenue is expected to be approximately $349 million, representing 4% year-over-year growth.
- The company anticipates achieving positive Adjusted EBITDA for the full year 2025.
- While business-to-business channels showed strong performance, Q4 results were impacted by a shift in the timing of a few large customer orders into the first half of 2026.
- Inogen plans to announce its full financial results and 2026 financial guidance on February 24, 2026.
Jan 12, 2026, 1:30 PM
Inogen Launches Aurora CPAP Masks for Obstructive Sleep Apnea
INGN
Product Launch
New Projects/Investments
- Inogen, Inc. (Nasdaq: INGN) has launched Aurora CPAP masks in the United States, marking its entry into the obstructive sleep apnea (OSA) market.
- This launch represents a pivotal step in Inogen's strategy to expand its respiratory care portfolio and addressable market opportunity within the growing sleep-therapy market.
- The Aurora Mask portfolio, which includes F1 Full Face, N1 Nasal Cushion, and P1 Nasal Pillows, is designed for comfort, reliability, and usability, and is FDA 510(k) Cleared.
Jan 7, 2026, 1:30 PM
Quarterly earnings call transcripts for Inogen.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more